A Vertical Cannabis Company in the Making
March 22nd, 2022
Exclusive, News, Top News
In the cannabis industry there are several business models that may make sense, depending on a company’s capabilities, people, and markets. There are wholesalers, distributors, retailers, propagators, brand houses, laboratories, multi-state operators … the list goes on. If a company puts all the right pieces together, a vertically integrated model could make sense to keep as much of the money and as many of the variables as possible in house.
Pharmagreen Biotech, Inc. (OTCQB: PHBI) is an early-stage company that believes in the vertical integration model and has many of the pieces already in place to launch a comprehensive cannabis company in the lucrative California market. Here we’ll take a look at Pharmagreen’s ingredients and the company’s step-by-step recipe to create a major player in the industry.
What Pharmagreen Has
Pharmagreen was founded around a proprietary tissue culture process known as Chibafreen™. The traditional process of tissue-culturing plants encompasses four steps: 1) Initiation, 2) Multiplication, 3) Rooting, and 4) Hardening. Pharmagreen’s COO, Dr. Fawzia Afreen, developed Chibafreen as a novel way to combine two of the steps, thereby increasing efficiency and profitability.
Chibafreen is applicable to a broad range of agricultural operations, but its value to cannabis and hemp farmers is enormous. Cannabis is a very complex plant with nearly endless combinations of terpenes and cannabinoids providing the basis for a wide variety of strains. Tissue culture propagation allows growers to lock in a repeatable genetic profile that guarantees consistency from one generation to the next, avoiding the common problem of genetic drift. This type of consistency is essential for both medicinal strains and retail brands, as consumers and patients alike need to be able to buy the same product over time.
Tissue culture is a key tool in eliminating diseases, contaminants, and pests from cannabis cultivation. The stability of the strains also allows growers to standardize and optimize feeding and fertilizing schedules that work best with each varietal.
With that technology in its bag, Pharmagreen went on a search to find the right location and market for its business. As often happens in the cannabis industry, the search led the company to California. Specifically, to Leggett, in Northern California’s renowned Mendocino County. Pharmagreen has an agreement to acquire Long Valley Farms, LLC, a cultivator with a legacy license in the state. The legacy status ensures the license will be grandfathered in regardless of the terms of the state’s anticipated new licensing system.
Long Valley Farms is a veganic grower working on a 12-acre property in the Leggett area. Veganic farming takes organic farming a step further as it doesn’t use any animal-based products such as bone meal, fish emulsion, or manure for fertilizer. Long Valley Farms is a no spray operation and utilizes on-site, plant-based materials to fertilize and encourage the growth of beneficial microbes and bacteria.
The agreement would make Long Valley Farms a wholly owned subsidiary of Pharmagreen, and would include the land, licenses, and current operations of the company. Once the deal is finalized, Pharmagreen intends to build a state-of-the-art, Internet of Things greenhouse facility to expand the cannabis cultivation capacity on site.
The Plan Going Forward
Pharmagreen is looking at a 5 month timeline to build the greenhouse once Long Valley Farms is acquired, with crops harvested every two months following completion of the facility. Once the greenhouse is built, the company intends to focus on the development of its tissue culture facility. This facility will not only make the Long Valley Farms operation better and more efficient, it will also provide a separate revenue stream for Pharmagreen as a whole.
There is a shorter-term path to revenue for the company, and it involves the processing of live rosin from existing grow operations. Extracts from cannabis plants are a major growth sector of the industry, but most extraction methods (like ethanol, CO₂, butane, etc.) tend to destroy many of the terpenes and cannabinoids from the original plant in search of one active ingredient like CBD or THC. Live rosin extraction uses a whole plant press without solvents to create an extract with all the active ingredients of the original plant.
Active cannabis ingredients are thought to work best in concert with each other, through a phenomenon called the Entourage Effect. The live rosin process preserves that effect while providing an extract that can be used to make the types of derived products, like edibles and topicals and vape pens, that are becoming so prevalent in the industry.
Pharmagreen has the equipment necessary to produce about $18,000 of live rosin per day. The company has applied for a local manufacturing license that will allow them to immediately start production and is also eyeing opportunities in the Leggett area with established licenses for lease to jump start revenue generation.
So, the plan for Pharmagreen’s corporate development looks like this:
- Step 1 – Live rosin production and sales. Very near term and immediate revenue generation once licensed.
- Step 2 – Finalize Long Valley Farms asset, license, and land acquisition and begin 5 month greenhouse build. Near term.
- Step 3 – Establish and expand brands in concert with increased production capacity.
- Step 4 – Expand with Chibafreen tissue culture facility. Approximately 2 years from now.
- Step 5 – Offer ancillary services such as DNA testing and cold storage associated with tissue culture.
Pharmagreen Biotech represents an early-stage investment opportunity in California, one of the world’s largest and most mature legal cannabis markets. Pharmagreen has an incremental and reasonable development plan, with many key assets in place. The company is committed to transparency with its investors and has recently uplisted to the OTCQB market, with the attendant heightened requirements.
There is much more to discuss regarding Pharmagreen, including the people who run the company, a deeper dive into the tissue culture technology, and a look at the benefits of veganic farming (both from an agricultural and marketability standpoint). We will be getting to those topics and more. For now, keep an eye on Pharmagreen as it advances the manufacturing and sale of live rosin, the acquisition of Long Valley Farms, and subsequent greenhouse build.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.